IE33929L - Adamantanyl alkylamines - Google Patents
Adamantanyl alkylaminesInfo
- Publication number
- IE33929L IE33929L IE691170A IE117069A IE33929L IE 33929 L IE33929 L IE 33929L IE 691170 A IE691170 A IE 691170A IE 117069 A IE117069 A IE 117069A IE 33929 L IE33929 L IE 33929L
- Authority
- IE
- Ireland
- Prior art keywords
- group
- atom
- hydrogen
- hydrogen atom
- alkyl group
- Prior art date
Links
- -1 Adamantanyl alkylamines Chemical class 0.000 title abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 12
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 6
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract 3
- 229910052801 chlorine Inorganic materials 0.000 abstract 3
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 230000001430 anti-depressive effect Effects 0.000 abstract 2
- 239000000935 antidepressant agent Substances 0.000 abstract 2
- 229940005513 antidepressants Drugs 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 abstract 1
- 208000027089 Parkinsonian disease Diseases 0.000 abstract 1
- 206010034010 Parkinsonism Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 125000006392 alkylpyrimidinyl group Chemical group 0.000 abstract 1
- 239000002830 appetite depressant Substances 0.000 abstract 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 201000003152 motion sickness Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/132—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing rings
- C07C53/136—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing rings containing condensed ring systems
- C07C53/138—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing rings containing condensed ring systems containing an adamantane ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/38—Acyl halides
- C07C53/44—Acyl halides containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/36—Acyl halides
- C07C55/38—Acyl halides containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
- C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
- C07D295/03—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/56—Ring systems containing bridged rings
- C07C2603/58—Ring systems containing bridged rings containing three rings
- C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
- C07C2603/74—Adamantanes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Catalysts (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Pivots And Pivotal Connections (AREA)
- Physical Or Chemical Processes And Apparatus (AREA)
Abstract
1,274,652. Antidepressant &c. compositions. LILLY INDUSTRIES Ltd. 28 Oct., 1969 [27 Aug., 1968], No. 40968/68. Heading A5B. [Also in Division C2] Pharmaceutical compositions having antidepressant, -Parkinsonism and -motion sickness and appetite suppressant activity comprise, as active ingredient, at least one 1-aminoalkyladamantane of the general formula wherein n is 1 or 2; R<SP>1</SP> is a hydrogen atom or a C 1-4 alkyl group or, when n is 1, R<SP>1</SP> and R<SP>4</SP> together form a methylene group; R<SP>2</SP> is a hydrogen atom or C 1-4 alkyl group or, when n is 1, a C 1-4 hydroxyalkyl or phenyl-C 1- 4 alkyl group, R<SP>3</SP> is a hydrogen atom or a C 1-4 alkyl group or, when R<SP>2</SP> is a hydrogen atom, R<SP>3</SP> is an amidino, pyrimidinyl or C 1-4 alkylpyrimidinyl group, or NR<SP>2</SP>R<SP>3</SP> is a pyrrolidino, piperidino, NC 1-4 alkylpiperazino or N-C 1-4 hydroxyalkylpiperazino group; R<SP>4</SP> is a hydrogen or chlorine atom or a phenyl group or, when n is 1, a bromine atom or cyclohexyl group; R<SP>5</SP> and R<SP>6</SP> are each a hydrogen atom or, when n is 1, a chlorine atom or phenyl group; provided that one of R<SP>4</SP>, R<SP>5</SP> and R<SP>6</SP> is not a chlorine atom and the others are hydrogen atoms or R<SP>4</SP> is not a bromine atom and R<SP>5</SP> and R<SP>6</SP> are hydrogen atoms, when R<SP>7</SP>, R<SP>8</SP> and R<SP>9</SP> are hydrogen atoms, R<SP>1</SP> is a hydrogen atom or a C 1-4 alkyl group, one of R<SP>2</SP> and R<SP>3</SP> is a hydrogen atom and the other is a C 1-4 alkyl group and n is 1; R<SP>7</SP> is a hydrogen or bromine atom or a hydroxyl or -(CH 2 ) n - -CHR a <SP>1</SP>-NR a <SP>2</SP>R a <SP>3</SP> group, wherein n is 1 or 2 and R a <SP>1</SP>, R a <SP>2</SP> and R a <SP>3</SP> are each a hydrogen atom or a C 1-4 alkyl group, or, when n is 1, R<SP>7</SP> is a methyl group; and R<SP>8</SP> and R<SP>9</SP> are each a hydrogen atom or, when n is 1, a methyl group; or pharmaceutically acceptable acid addition salt thereof, in association with a pharmaceutically acceptable carrier.
[GB1274652A]
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB40968/68A GB1274652A (en) | 1968-08-27 | 1968-08-27 | Adamantanyl-alkylamine derivatives and their preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IE33929L true IE33929L (en) | 1970-02-27 |
| IE33929B1 IE33929B1 (en) | 1974-12-11 |
Family
ID=10417493
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IE1170/69A IE33929B1 (en) | 1968-08-27 | 1969-08-27 | Adamantanyl alkylamine derivatives and their preparation |
Country Status (12)
| Country | Link |
|---|---|
| JP (3) | JPS4939257B1 (en) |
| AT (1) | AT307380B (en) |
| BE (1) | BE737975A (en) |
| CH (3) | CH553149A (en) |
| DE (1) | DE1943404A1 (en) |
| DK (1) | DK131721C (en) |
| FR (1) | FR2016468B1 (en) |
| GB (1) | GB1274652A (en) |
| IE (1) | IE33929B1 (en) |
| IL (1) | IL32892A (en) |
| NL (1) | NL6913046A (en) |
| SE (1) | SE364037B (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS507356A (en) * | 1973-05-22 | 1975-01-25 | ||
| GB0013737D0 (en) | 2000-06-07 | 2000-07-26 | Astrazeneca Ab | Novel compounds |
| SE0103836D0 (en) * | 2001-11-16 | 2001-11-16 | Astrazeneca Ab | Novel compounds |
| SE0300480D0 (en) | 2003-02-21 | 2003-02-21 | Astrazeneca Ab | Novel compounds |
| GB0312609D0 (en) | 2003-06-02 | 2003-07-09 | Astrazeneca Ab | Novel compounds |
| ITTO20030668A1 (en) | 2003-09-02 | 2005-03-03 | Rotta Res Lab S P A O Ra Rottapharm | DERIVATIVES OF ADAMANTAN EQUIPPED WITH NEUROPROTECTIVE, ANTIDEPRESSIVE AND ANTI-ISCHEMIC ACTIVITY AND PROCEDURE FOR THEIR PREPARATION. |
| RU2460727C2 (en) | 2007-03-22 | 2012-09-10 | Астразенека Аб | Quinoline derivatives for treating inflammatory diseases |
| PE20091036A1 (en) | 2007-11-30 | 2009-08-15 | Astrazeneca Ab | QUINOLINE DERIVATIVE AS ANTAGONIST OF THE P2X7 RECEPTOR |
| CN109593042B (en) * | 2018-12-24 | 2021-12-07 | 陕西莱特迈思光电材料有限公司 | Organic electroluminescent material and organic electroluminescent device comprising same |
| CN114181091B (en) * | 2021-12-27 | 2024-06-14 | 维思普新材料（苏州）有限公司 | Synthesis process of adamantane triphenylamine |
| CN116947644B (en) * | 2023-07-26 | 2025-01-24 | 山东轩鸿生物医药有限公司 | A kind of preparation method of memantine hydrochloride |
-
1968
- 1968-08-27 GB GB40968/68A patent/GB1274652A/en not_active Expired
-
1969
- 1969-08-25 IL IL6932892A patent/IL32892A/en unknown
- 1969-08-26 DK DK457869A patent/DK131721C/en active
- 1969-08-26 SE SE11809/69A patent/SE364037B/xx unknown
- 1969-08-26 AT AT817269A patent/AT307380B/en active
- 1969-08-26 DE DE19691943404 patent/DE1943404A1/en active Pending
- 1969-08-26 CH CH143372A patent/CH553149A/en not_active IP Right Cessation
- 1969-08-26 CH CH1300669A patent/CH538442A/en not_active IP Right Cessation
- 1969-08-26 NL NL6913046A patent/NL6913046A/xx unknown
- 1969-08-26 CH CH1435971A patent/CH551365A/en not_active IP Right Cessation
- 1969-08-26 BE BE737975A patent/BE737975A/xx unknown
- 1969-08-27 FR FR696929356A patent/FR2016468B1/fr not_active Expired
- 1969-08-27 IE IE1170/69A patent/IE33929B1/en unknown
-
1972
- 1972-06-29 JP JP47064563A patent/JPS4939257B1/ja active Pending
- 1972-06-29 JP JP47064562A patent/JPS4939256B1/ja active Pending
- 1972-06-29 JP JP47064561A patent/JPS5010856B1/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| GB1274652A (en) | 1972-05-17 |
| FR2016468B1 (en) | 1973-06-08 |
| FR2016468A1 (en) | 1970-05-08 |
| NL6913046A (en) | 1970-03-03 |
| SE364037B (en) | 1974-02-11 |
| BE737975A (en) | 1970-02-26 |
| JPS4939257B1 (en) | 1974-10-24 |
| DK131721C (en) | 1976-01-26 |
| CH553149A (en) | 1974-08-30 |
| CH538442A (en) | 1973-06-30 |
| IL32892A0 (en) | 1969-11-12 |
| JPS5010856B1 (en) | 1975-04-24 |
| AT307380B (en) | 1973-05-25 |
| JPS4939256B1 (en) | 1974-10-24 |
| DE1943404A1 (en) | 1970-12-17 |
| DK131721B (en) | 1975-08-25 |
| IE33929B1 (en) | 1974-12-11 |
| IL32892A (en) | 1975-04-25 |
| CH551365A (en) | 1974-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IE33929B1 (en) | Adamantanyl alkylamine derivatives and their preparation | |
| GB1185522A (en) | 00,5-(Iminomethano)-10,11-Dihydro-5H-Dibenzo [a,d]Cycloheptene and Derivatives | |
| GB1296544A (en) | ||
| GB1352257A (en) | Pyridyltriazoles their preparation and compositions containing them | |
| GB1322451A (en) | 3-amino-5-benzyl-1,2,4-oxadiazoles | |
| ES339432A1 (en) | Novel halo-substituted tetrahydro-quinazolines | |
| GB1177145A (en) | Heterocyclic Allylic Amines | |
| GB1352392A (en) | Phenylisopropylamine derivatives | |
| GB1314899A (en) | Thiosemicarbazones processes for their preparations and compositions incorporating them | |
| GB1405767A (en) | Method formulation and pharmaceutical composition for reducing plasma lipid levels | |
| GB1353486A (en) | Benzodiazepine derivatives | |
| GB1193438A (en) | Barbituric Acid Derivatives, preparation thereof and Pharmaceutical Compositions containing them | |
| GB1270831A (en) | Di-hydro triazine derivatives and processes for their manufacture | |
| GB1195319A (en) | Alkyl Sulfate Salts of 1-(p-Chlorobenzhydryl)-4-Methylhomopiperazines | |
| GB1257264A (en) | ||
| ES385522A1 (en) | Azamorphinan compounds | |
| SE320076B (en) | ||
| GB1273399A (en) | Novel formamido-cycloalkane derivatives | |
| IE33462B1 (en) | Benzodioxole compounds | |
| IE34313L (en) | 2-hydroxy-5-aminobenzamides | |
| GB1292745A (en) | 4-alkyl-diphenylmethoxy-alkylamines and acid addition salts and pharmaceutical compositions thereof | |
| IE780530L (en) | Anti-histamine salts and compositions | |
| GB1317125A (en) | Piperazine compositions and method of treatment | |
| GB1316702A (en) | Substituted piperazine derivatives | |
| GB1491358A (en) | Pharmaceutical materials |